Inequities in access to biologic and synthetic DMARDs across 46 European countries

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

(2013) Ewa Orlewska et al.   MEDICAL SCIENCE MONITOR

Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RA

(2012) Polina Putrik et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries

(2011) Joëlle M. Hoebert et al.   HEALTH POLICY

Patient Access to New Cancer Drugs in the United States and Australia

(2011) Andrew Wilson et al.   VALUE IN HEALTH

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009

(2010) M Neovius et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Comparison of Anti-TNF Treatment Initiation in Rheumatoid Arthritis Databases Demonstrates Wide Country Variability in Patient Parameters at Initiation of Anti-TNF Therapy

(2010) Chris Pease et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: A systematic review

(2010) Gabrielle van der Velde et al.   ARTHRITIS CARE & RESEARCH

Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database

(2009) T Sokka et al.   ANNALS OF THE RHEUMATIC DISEASES